- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05089747
CIRculating CANcer MAster-Protocol (CIRCAN MAP)
July 21, 2023 updated by: Hospices Civils de Lyon
MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
6000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sebastian Couraud, MD, PhD
- Phone Number: +33 4 478 864 401
- Email: sebastien.couraud@chu-lyon.fr
Study Locations
-
-
-
Bron, France, 69500
- Recruiting
- Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est
-
Contact:
- Michaël DURUISSEAUX, Dr
- Email: michael.duruisseaux@chu-lyon.fr
-
Lyon, France, 69004
- Recruiting
- Service de Pneumologie Hôpital Croix-Rousse / Groupement Hospitalier Nord
-
Contact:
- Lize KIAKOUAMA-MALEKA, Dr
- Email: lize.kiakouama-maleka@chu-lyon.fr
-
Pierre-Bénite, France, 69310
- Recruiting
- Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud / Groupement Hospitalier Sud
-
Contact:
- Sebastien COURAUD, MD, PhD
- Phone Number: +33 4 478 864 401
- Email: sebastien.couraud@chu-lyon.fr
-
Pierre-Bénite, France, 69495
- Recruiting
- Oncologie médicale Hôpital Lyon-Sud / Groupement Hospitalier Sud
-
Contact:
- Gilles FREYER, Pr
- Email: gilles.freyer@chu-lyon.fr
-
Pierre-Bénite, France, 69495
- Recruiting
- Service de dermatologie Hôpital Lyon-Sud / Groupement Hospitalier Sud
-
Contact:
- Stéphane DALLE, Pr
- Email: stephane.dalle@chu-lyon.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adult with solid cancer
Description
Inclusion Criteria:
- Adult (>18y)
- Owing a social security insurance
- Any solid cancer diagnosed by histopathology or cytology
- Patient with blood sampling required as per standard of care
- Informed consent signed
Exclusion Criteria:
- Refusal to participate
- No blood sampling required as per standard of care
- Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
- Heterologous blood transfusion in the last 48 hours
- Weight under 20 kg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Adult with solid cancer. No intervention.
|
From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liquid biopsy analyses
Time Frame: Day 0
|
Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.
|
Day 0
|
Standard technics of disease assessment
Time Frame: Week 16
|
Genetic and transcriptomic explorations with immunofluorescence technique.
Marking with specific markers of the tumor pathology.
And enumaration of tumoral cells.
|
Week 16
|
Correlation between outcome 1 and outcome 2
Time Frame: year 5
|
Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.
|
year 5
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2022
Primary Completion (Estimated)
December 1, 2047
Study Completion (Estimated)
December 1, 2047
Study Registration Dates
First Submitted
October 11, 2021
First Submitted That Met QC Criteria
October 21, 2021
First Posted (Actual)
October 22, 2021
Study Record Updates
Last Update Posted (Estimated)
July 24, 2023
Last Update Submitted That Met QC Criteria
July 21, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 69HCL21_0918
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult With Solid Cancer
-
3H (Suzhou) Pharmaceuticals Co., Ltd.Not yet recruitingSolid Tumors With FGFR2 Alterations, AdultUnited States
-
3H (Suzhou) Pharmaceuticals Co., Ltd.Not yet recruitingSolid Tumors With FGFR2 Alterations, AdultChina
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
University College, LondonCancer Research UKRecruitingCancer | Solid Tumor, AdultUnited Kingdom
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Institut CurieActive, not recruiting
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
HotSpot Therapeutics, IncRecruitingSolid Tumor, Adult | Relapsed Cancer | Refractory CancerUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor, Adult | Refractory Cancer | Relapsed Solid Neoplasm
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
Clinical Trials on Blood sampling for biomarker analysis (microRNA, circulating DNA…)
-
University Hospital, RouenUnknownMetastatic Colorectal Cancer | Circulating MarkersFrance
-
University of L'AquilaNovartisActive, not recruiting
-
Abramson Cancer Center at Penn MedicineRecruiting
-
Central Hospital, Nancy, FranceCompletedDiastolic Heart Failure
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Rigshospitalet, DenmarkCompleted
-
University of AthensUniversity of Jena; General Hospital of LamiaCompleted
-
University Hospital, BordeauxCompletedPain | Fabry's DiseaseFrance
-
Progenity, Inc.CompletedDown Syndrome | Aneuploidy | DiGeorge Syndrome | Turner Syndrome | Klinefelter Syndrome | Chromosome Deletion | Edwards Syndrome | Patau SyndromeUnited States
-
Beth Israel Deaconess Medical CenterJoslin Diabetes Center; Chan Zuckerberg InitiativeRecruitingObesity | Adipose Tissue | Adipose Tissue, BrownUnited States